We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Pediatrics

Pediatrics

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Single low‑dose primaquine (0.25 mg/kg) is safe and effective for blocking Plasmodium falciparum transmission in children and adults
Infectious DiseasesPrimaquinesafety

Single low‑dose primaquine (0.25 mg/kg) is safe and effective for blocking Plasmodium falciparum transmission in children and adults

By MedXY|Nov 23, 2025

A pooled individual‑patient meta‑analysis (6056 participants) shows single low‑dose primaquine (0.25 mg/kg) added to ACTs reduces gametocyte carriage and mosquito infectivity across ages and transmission settings without increasing clinical

An 18‑Month VLA15 Booster Elicits Robust Anti‑OspA Responses and Shows Favorable Tolerability Across Ages
Infectious DiseasesLyme disease

An 18‑Month VLA15 Booster Elicits Robust Anti‑OspA Responses and Shows Favorable Tolerability Across Ages

By MedXY|Nov 23, 2025

An 18‑month booster of the VLA15 Lyme vaccine candidate produced strong anamnestic anti‑OspA IgG responses exceeding primary‑series levels in children, adolescents, and adults, with a tolerability profile similar to primary doses.

Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
Critical CareMycoplasma pneumoniaePediatrics

Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications

By MedXY|Nov 23, 2025

A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Infectious Diseasesimmunobridginginfluenza vaccine

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

By MedXY|Nov 23, 2025

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited react

Peer Self-harm Predicts a Small Increase in Adolescent Risk with a Peak at Age 16: Findings from a Nationwide Finnish Cohort
newsadolescentsself-harm

Peer Self-harm Predicts a Small Increase in Adolescent Risk with a Peak at Age 16: Findings from a Nationwide Finnish Cohort

By MedXY|Nov 23, 2025

A Finnish registry cohort (n=913,149) found that exposure to same-grade schoolmates’ self-harm modestly increased later self-harm risk (HR 1.05), with the largest effect around age 16 (HR ~1.45), suggesting time-limited social transmi

Maternal Paracetamol in Pregnancy and Child Neurodevelopment: Current Evidence Does Not Establish a Clear Causal Link
newsADHDautism

Maternal Paracetamol in Pregnancy and Child Neurodevelopment: Current Evidence Does Not Establish a Clear Causal Link

By MedXY|Nov 22, 2025

An umbrella review of systematic reviews finds low to critically low confidence in studies linking prenatal paracetamol exposure to autism or ADHD; sibling-controlled analyses largely attenuate associations. Clinical guidance: use lowest ef

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids
Cardiologyadenotonsillectomyblood pressure

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids

By MedXY|Nov 20, 2025

An exploratory analysis of the PATS randomized trial found early adenotonsillectomy reduced 12‑month systolic and diastolic BP percentiles versus watchful waiting in children with mild obstructive sleep‑disordered breathing, with larger DBP

Adenotonsillectomy vs Watchful Waiting in Young Children with Mild–Moderate OSA: Long-term Findings from the KATE Randomized Trial
newsadenotonsillectomypediatric OSA

Adenotonsillectomy vs Watchful Waiting in Young Children with Mild–Moderate OSA: Long-term Findings from the KATE Randomized Trial

By MedXY|Nov 19, 2025

The KATE trial (n=60) found no between-group difference in polysomnographic OAHI change after 3 years, though adenotonsillectomy improved disease-specific quality of life. Nearly 42% of watchful-waiting children later underwent surgery, sug

General Practice Follow-up After Pediatric Ventilation Tube Insertion Is Noninferior to ENT Surveillance: Results from the ConVenTu Trial
newsPediatricsprimary care

General Practice Follow-up After Pediatric Ventilation Tube Insertion Is Noninferior to ENT Surveillance: Results from the ConVenTu Trial

By MedXY|Nov 19, 2025

A multicenter randomized noninferiority trial found that GP observation after pediatric ventilation tube insertion produced audiometric outcomes at 2 years that were noninferior to routine ENT follow-up, with no increase in complications.

Acute Kidney Injury in Extremely Preterm Infants Predicts Higher Risk of Death or Neurodevelopmental Impairment at Two Years
Nephrologyacute kidney injuryneurodevelopment

Acute Kidney Injury in Extremely Preterm Infants Predicts Higher Risk of Death or Neurodevelopmental Impairment at Two Years

By MedXY|Nov 19, 2025

Secondary analysis of the PENUT trial found that acute kidney injury (AKI) in infants born at 24–27 weeks’ gestation is independently associated with death or moderate to severe neurodevelopmental impairment at 22–26 months’ corrected

Weight Trajectories Among Youths Following Residential Relocation
newsair pollutionBody Mass Index

Weight Trajectories Among Youths Following Residential Relocation

By MedXY|Nov 19, 2025

This study explores how changes in residential environments affect childhood BMI, focusing on air pollution, built environment, and socioeconomic factors across cohorts in the Netherlands, Sweden, and Czech Republic.

Community Health Workers Halt Decline in Quality of Life During Transition to Adult Care for Young Adults With Sickle Cell Disease
Hematology-Oncologycommunity health workersmobile health

Community Health Workers Halt Decline in Quality of Life During Transition to Adult Care for Young Adults With Sickle Cell Disease

By MedXY|Nov 17, 2025

A multicenter randomized trial found that community health worker support produced modest but durable improvements in health-related quality of life for young adults with sickle cell disease during transition to adult care, whereas a mobile

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use
newsadolescentsmetformin

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

By MedXY|Nov 17, 2025

A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipola

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice
newsadolescentsbipolar disorder

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

By MedXY|Nov 17, 2025

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with se

CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial
Hematology-OncologyCPX-351Down syndrome

CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial

By MedXY|Nov 17, 2025

In the ML‑DS 2018 trial, substituting reduced‑intensity induction with CPX‑351 led to lower 24‑month event‑free survival (69% vs 90%) despite excellent overall survival and minimal treatment‑related mortality; MRD by GATA1 NGS, trisomy 8 an

Is the Gut Microbiome Really a Key to Understanding Autism?
Neurologyautismgut microbiome

Is the Gut Microbiome Really a Key to Understanding Autism?

By MedXY|Nov 13, 2025

A critical review highlights serious flaws in research linking gut microbiome to autism, questioning its causal role and urging more rigorous studies or reconsideration of this research path.

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
HIV/AIDSHIVPediatrics

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

By MedXY|Nov 13, 2025

A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuation

Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns
HIV/AIDSdolutegravirHIV

Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns

By MedXY|Nov 12, 2025

First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegr

Very Early Neonatal ART Enables ART‑Free HIV‑1 Remission in Some Children: Clinical Insights from IMPAACT P1115
HIV/AIDSpediatric HIV

Very Early Neonatal ART Enables ART‑Free HIV‑1 Remission in Some Children: Clinical Insights from IMPAACT P1115

By MedXY|Nov 12, 2025

IMPAACT P1115 shows that initiating combination ART within 48 hours of birth can enable sustained ART‑free HIV‑1 remission for 48+ weeks in a subset of children with in‑utero infection, but careful selection, close monitoring and standardiz

Genomic Newborn Screening Is Feasible, Highly Acceptable and Clinically Actionable: Lessons from the BabyScreen+ Cohort
newsimplementationnewborn screening

Genomic Newborn Screening Is Feasible, Highly Acceptable and Clinically Actionable: Lessons from the BabyScreen+ Cohort

By MedXY|Nov 12, 2025

BabyScreen+ shows clinically accredited whole‑genome sequencing from dried blood spots can be integrated into newborn screening at scale: 1.6% of 1,000 babies had high‑chance actionable findings, median return 13 days, strong parental accep

Prev
16 / 25
1…1415161718…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles